Romanian pharmaceutical company Antibiotice (BVB: ATB) has entered into a loan agreement with the European Investment Bank (EIB), securing EUR 25 million. This loan will partially fund a significant investment venture totaling EUR 95.4 million. The project includes constructing a modern facility for production, packaging, and storage, alongside the introduction of new production lines and enhancements in digitalization, research, and development capabilities.

As outlined in a joint press release by both entities, the initiative is set to bolster advanced pharmaceutical manufacturing capabilities in Romania.

One of the key outcomes of this investment is the anticipated growth in Antibiotice's research and development sector, focusing on innovating new pharmaceuticals and production methodologies. This advancement is expected to create around 100 full-time positions in research and manufacturing over the next four years, contributing to job opportunities for highly skilled professionals. Antibiotice's existing collaborations with universities and research institutes further augment this employment potential.

The EUR 25 million loan from the EIB is backed by the European Union under the InvestEU programme. InvestEU aims to catalyze additional investments exceeding EUR 372 billion between 2021 and 2027. The Fund, operational through the EU's financial partners like the EIB, leverages an EU budget guarantee of EUR 26.2 billion to finance various projects.